Items tagged with Treatment

The Medicines Patent Pool and Otsuka sign Memorandum of Understanding for paediatric formulations of delamanid for multidrug-resistant TB (post)

Geneva, 11 October 2017 — The Medicines Patent Pool (MPP) announced that it has signed a Memorandum of Understanding (MoU) with Otsuka to accelerate the development and manufacturing of, and access to, paediatric formulations containing delamanid for multidrug-resistant tuberculosis (MDR-TB).

Highlights from the 48th Union World Conference on Lung Health (post)

Metformin reduces mortality during TB therapy (post)

According to a recent study published in Clinical Infectious Diseases, the presence of diabetes mellitus (DM) increases risk for mortality during tuberculosis treatment, but metformin use may counteract that risk.

The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? (post)

Abstract

Philippines uses PViMS app to roll out groundbreaking TB drug (post)

The Philippines has one of the highest TB burdens in the world—and 2.6% of its more than 286,000 new cases in 2015 were of multi-drug-resistant TB (MDR-TB). This threatens the progress the country has made in addressing the deadly disease over the past few decades and its goal to make the country TB-free by 2030. Further, MDR-TB cases will likely rise steadily in the Philippines and the world over the next two decades.

New TB drugs are more effective and may be less toxic. Why are they still unavailable? (post)

The start of 2017 saw concern over a sharp increase in the rise of drug-resistant TB in South Africa. TB is killing millions each year. Last week, Médecins Sans Frontières published promising early data on the use of two new TB drugs, delamanid and bedaquiline, among patients living with drug-resistant TB in Khayelitsha, Cape Town. But availability remains the biggest concern.

48th Union World Conference: “While these drugs are new to the TB world, they’ve been around for a long time . . .” (post)

At a conference focused on “Accelerating toward elimination” attention turns again to stalled rollouts of the most promising medicines and regimens.

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin (post)

Twice-daily tenofovir alafenamide (TAF) plus rifampicin provided similar exposures to once-daily TAF in pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.

MPP and TB Alliance sign Memorandum of Understanding to support further development of sutezolid (post)

Geneva, 31 October 2017 — The Medicines Patent Pool (MPP) and TB Alliance signed a Memorandum of Understanding (MoU) to facilitate third-party development of sutezolid-containing tuberculosis regimens. The MoU follows the sublicensing agreement signed by both organisations in March 2017 granting TB Alliance the rights to develop sutezolid, a promising antibiotic drug candidate, in combination with other TB drugs for drug-susceptible and drug-resistant TB patients.

Report: TB medicine crisis in Romania (post)

Authorities in Romania are unable to provide the full range of essential medicines needed for the treatment of TB, the Romanian Health Observatory said in its latest report, TB medicine crisis in Romania. While the contagious disease is designated a public health priority in the country, the root cause is “the existence of absurd and self-contradictory legislation and widespread government red tape” that blocks Romanian tuberculosis patients’ access to treatment, it said.